Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
No lethal dose has been established in animal studies, even at dosages many orders of magnitude higher than those used in therapeutic research
April 2026 Category 2 Update On April 15, 2026, the FDA confirmed removal of injectable GHK-Cu from Category 2 because the original nominations were withdrawn
$225.00 / month
Qualified researchers who are readers of Peptides.org can receive a 10% discount on their next order at Limitless Life
Tirzepatide is a dual-agonist (GLP-1 + GIP)
US$ 28.56
US$ 27.62
US$ 22.61
US$ 23.22
US$ 22.24
US$ 21.82
US$ 20.85
